Sangamo Therapeutics Inc (NASDAQ:SGMO) VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $17.11, for a total transaction of $85,550.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Sangamo Therapeutics Inc (SGMO) traded down $1.55 during midday trading on Friday, reaching $19.65. 1,815,495 shares of the company’s stock traded hands, compared to its average volume of 1,280,000. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64. Sangamo Therapeutics Inc has a twelve month low of $3.55 and a twelve month high of $21.90. The firm has a market cap of $1,540.00, a PE ratio of -28.48 and a beta of 2.87.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The business had revenue of $11.81 million during the quarter, compared to analysts’ expectations of $10.37 million. During the same period in the previous year, the business posted ($0.27) EPS. The business’s quarterly revenue was up 333.0% compared to the same quarter last year. sell-side analysts forecast that Sangamo Therapeutics Inc will post -0.73 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Quantbot Technologies LP acquired a new stake in Sangamo Therapeutics during the 3rd quarter valued at approximately $118,000. Amalgamated Bank acquired a new stake in Sangamo Therapeutics during the 3rd quarter valued at approximately $158,000. Chicago Equity Partners LLC acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $192,000. Great West Life Assurance Co. Can lifted its stake in shares of Sangamo Therapeutics by 150.3% in the 3rd quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 7,667 shares during the period. Finally, Principal Financial Group Inc. lifted its stake in shares of Sangamo Therapeutics by 6.8% in the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 832 shares during the period. Institutional investors and hedge funds own 64.09% of the company’s stock.
A number of research firms recently commented on SGMO. BidaskClub upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, January 24th. Jefferies Group reiterated a “buy” rating and issued a $18.00 target price on shares of Sangamo Therapeutics in a research note on Friday, October 13th. Piper Jaffray Companies upgraded shares of Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 target price for the company in a research note on Wednesday, November 15th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Wednesday, November 15th. Finally, Barclays began coverage on shares of Sangamo Therapeutics in a research note on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 target price for the company. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $18.83.
TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/03/edward-r-conner-sells-5000-shares-of-sangamo-therapeutics-inc-sgmo-stock.html.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.